Home > Protocol Summaries: Compounds > GW876008

Protocol Summaries: GW876008

GSK Study ID	Phase	Title	Status
CRH103002	Phase 1	An open-label, repeat-dose, single-sequence study to investigate the effects of once-daily repeat oral administration of GW876008 125mg on the pharmacokinetics of the combined oral contraceptive in female volunteers	Terminated
CRH103004	Phase 1	An open-label, parallel group, single session study comparing the pharmacokinetics of a single oral dose of GW876008 administered to healthy volunteer smokers and healthy volunteer non-smokers.	Completed
CRH103152	Phase 1	An open-label, single-sequence study to evaluate the potential CYP 3A4 pharmacokinetic interaction of GW876008 in healthy subjects	Completed
CRH103390	Phase 2	Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD)	Completed
CRH104150	Phase 1	A randomized, placebo-controlled, double-dummy, four-way crossover design study to investigate the changes of fMRI BOLD activation induced by emotional activation paradigms following single doses of GW876008 and lorazepam (comparator) in healthy subjects.	Completed
CRI103143	Phase 2	A Phase IIa, single-centre, randomised, placebo-controlled, double-blind, three-period crossover study investigating the effects on gut autonomic responses of single administrations of either 20 mg or 200 mg GW876008, a CRF1 antagonist, to adult patients with irritable bowel syndrome	Completed
CRI109244	Phase 2	A double-blind, randomised, placebo-controlled, three-period crossover study to investigate the pharmacodynamic effect of two CRF-1 antagonists GSK561679 and GW876008 on meal induced cortisol responses in patients with IBS.	Terminated